We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00479505
First Posted: May 28, 2007
Last Update Posted: March 23, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Pfizer
  Purpose
This is a 12 week study in which different doses of UK-369,003 will be administered to patients with a diagnosis of overactive bladder. Patients will complete a series of questionnaires before treatment, during treatment and after treatment, to assess whether UK-369,003 has improved their symptoms of overactive bladder and erectile function.

Condition Intervention Phase
Urinary Bladder, Overactive Drug: UK-369,003 Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-Center, Randomised, Parallel Group, Double-Blind, Placebo Controlled Estimation Study To Assess The Efficacy And Safety Of Modified Release UK-369,003 In The Treatment Of Men With Storage Lower Urinary Tract Symptoms (LUTS) With And Without Erectile Dysfunction (ED).

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • This is an estimation study with no primary endpoint. There are efficacy endpoints. [ Time Frame: 12 Weeks ]

Secondary Outcome Measures:
  • Patient reported treatment impact questionnaire. [ Time Frame: 12 Weeks ]
  • Lower urinary tract symptoms diary. [ Time Frame: 12 Weeks ]
  • International prostate symptom score questionnaire. [ Time Frame: 12 Weeks ]
  • OAB-q short form questionnaire. [ Time Frame: 12 Weeks ]
  • Patient perception of bladder control questionnaire. [ Time Frame: 12 Weeks ]
  • International index of erectile function questionnaire. [ Time Frame: 12 Weeks ]
  • International consultation on incontinence questionnaire. [ Time Frame: 12 Weeks ]
  • Quality of erection questionnaire. [ Time Frame: 12 Weeks ]

Estimated Enrollment: 275
Study Start Date: June 2007
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Active Drug: UK-369,003
UK-369,003 100mg, 50mg, 25mg and 10mg doses in addition to placebo.
Placebo Comparator: Placebo Drug: Placebo
Placebo

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male subjects aged 18 years and above
  • documented clinical diagnosis of overactive bladder with urinary frequency >= 8 times / 24 hours and number of urgency episodes > 1 episode / 24 hours.

Exclusion Criteria:

  • Neurological diseases known to affect bladder function.
  • Urinary tract infection.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00479505


  Show 52 Study Locations
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer Inc
ClinicalTrials.gov Identifier: NCT00479505     History of Changes
Other Study ID Numbers: A3711047
First Submitted: May 24, 2007
First Posted: May 28, 2007
Last Update Posted: March 23, 2011
Last Verified: March 2011

Additional relevant MeSH terms:
Lower Urinary Tract Symptoms
Urinary Bladder, Overactive
Urological Manifestations
Signs and Symptoms
Urinary Bladder Diseases
Urologic Diseases